TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
1.110
+0.020 (1.83%)
Dec 20, 2024, 4:00 PM EST - Market closed
TherapeuticsMD Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Dec '24 Dec 20, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 13 | 26 | 53 | 151 | 358 | 656 | |
Market Cap Growth | -40.06% | -51.31% | -64.97% | -57.86% | -45.38% | -27.59% | |
Enterprise Value | 15 | 24 | 148 | 241 | 527 | 706 | |
Last Close Price | 1.11 | 2.25 | 5.59 | 17.77 | 60.50 | 121.00 | |
PE Ratio | - | - | 0.47 | - | - | - | |
PS Ratio | 7.94 | 19.79 | 0.76 | 58.71 | 5.53 | 13.22 | |
PB Ratio | 0.47 | 0.88 | 1.51 | -1.61 | -2.89 | 71.32 | |
P/TBV Ratio | 0.84 | 1.11 | 1.88 | - | - | - | |
EV/Sales Ratio | 9.49 | 18.28 | 2.12 | 93.74 | 8.13 | 14.22 | |
EV/EBITDA Ratio | - | - | 12.49 | - | - | - | |
EV/EBIT Ratio | - | - | 13.89 | - | - | - | |
Debt / Equity Ratio | 0.27 | 0.27 | 0.25 | -2.11 | -2.01 | 22.31 | |
Debt / EBITDA Ratio | - | - | 0.63 | - | - | - | |
Asset Turnover | 0.04 | 0.02 | 0.54 | 0.01 | 0.29 | 0.21 | |
Inventory Turnover | - | - | - | - | 1.61 | 0.84 | |
Quick Ratio | 1.40 | 1.08 | 0.81 | 0.26 | 1.91 | 3.49 | |
Current Ratio | 2.03 | 1.72 | 1.18 | 0.47 | 2.17 | 3.93 | |
Return on Equity (ROE) | -14.39% | -23.90% | - | - | - | -330.09% | |
Return on Assets (ROA) | -6.65% | -7.96% | 5.13% | -25.48% | -43.12% | -39.52% | |
Return on Capital (ROIC) | -8.46% | -13.12% | 9.01% | -39.12% | -56.92% | -49.02% | |
Earnings Yield | -25.90% | -39.89% | 211.63% | -114.14% | -51.20% | -26.84% | |
FCF Yield | -55.63% | -186.82% | -7.71% | -94.48% | -44.55% | -25.63% | |
Buyback Yield / Dilution | -9.82% | -11.48% | -17.66% | -44.39% | -11.89% | -9.48% | |
Total Shareholder Return | -9.82% | -11.48% | -17.66% | -44.39% | -11.89% | -9.48% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.